Second Sight Medical Products Inc. (EYES) Trading Up 3.7%
Second Sight Medical Products Inc. (NASDAQ:EYES) was up 3.7% on Tuesday . The company traded as high as $3.69 and last traded at $3.68, with a volume of 127,169 shares. The stock had previously closed at $3.55.
A number of equities research analysts have weighed in on EYES shares. Zacks Investment Research upgraded shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Friday, June 24th. Rodman & Renshaw reiterated a “buy” rating and set a $16.00 price target on shares of Second Sight Medical Products in a research note on Tuesday, July 26th.
The company’s 50 day moving average is $3.96 and its 200 day moving average is $4.39. The stock’s market cap is $145.59 million.
Second Sight Medical Products (NASDAQ:EYES) last announced its quarterly earnings data on Thursday, July 28th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.02. During the same quarter in the prior year, the company posted ($0.12) EPS. The firm earned $1.04 million during the quarter, compared to the consensus estimate of $2.66 million. The firm’s quarterly revenue was down 63.0% on a year-over-year basis. Analysts expect that Second Sight Medical Products Inc. will post ($0.62) earnings per share for the current fiscal year.
In other news, Chairman Robert J. Greenberg sold 8,571 shares of the company’s stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $4.10, for a total transaction of $35,141.10. Following the sale, the chairman now owns 172,911 shares in the company, valued at approximately $708,935.10. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.